Pictet & Cie (Europe) Sa Recursion Pharmaceuticals, Inc. Transaction History
Pictet & Cie (Europe) Sa
- $4.93 Billion
- Q3 2025
A detailed history of Pictet & Cie (Europe) Sa transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Pictet & Cie (Europe) Sa holds 1,630,000 shares of RXRX stock, worth $9.21 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
1,630,000Holding current value
$9.21 Million% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
289MCall Options Held
7.75MPut Options Held
6.1M-
Vanguard Group Inc Valley Forge, PA36.1MShares$204 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$186 Million1.38% of portfolio
-
Baillie Gifford & CO24MShares$135 Million0.09% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$97.8 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$82.9 Million0.31% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.02B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...